Brief: Revive Therapeutics Provides Update On FDA Phase 3 Clinical Trial For Bucillamine In COVID-19
26/10/2021 13:26
Oct 26 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS PROVIDES UPDATE ON FDA PHASE 3
CLINICAL
TRIAL FOR BUCILLAMINE IN COVID-19
* REVIVE THERAPEUTICS LTD - FINALIZING KEY RESEARCH OF
THIOL-BASED
DRUGS, INCLUDING BUCILLAMINE, AGAINST DELTA VARIANT OF COVID-19
* REVIVE THERAPEUTICS LTD - EXPECT TO COMPLETE ENROLLMENT IN
Q4-2021
* REVIVE THERAPEUTICS LTD - PHASE 3 CLINICAL TRIAL FOR
BUCILLAMINE TO INCORPORATE VIRAL LOAD TESTING FOR A MINIMUM OF
300 PATIENTS
* REVIVE THERAPEUTICS LTD - DSMB SUPPORT IN CONTINUING PHASE
3
BUCILLAMINE TRIAL ; NO SERIOUS ADVERSE EVENTS AND SAFETY
CONCERNS REPORTED TO DATE
* REVIVE THERAPEUTICS LTD - IN DISCUSSIONS WITH ITS
MANUFACTURING
PARTNER TO SECURE COMMERCIAL SUPPLY OF AT LEAST 5 BILLION
BUCILLAMINE TABLETS FOR 2022
Source text for Eikon: ID:nGNX6rpDzc
Further company coverage: RVV.CD
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure